| p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements P Campomenosi, P Monti, A Aprile, A Abbondandolo, T Frebourg, B Gold, ... Oncogene 20 (27), 3573-3579, 2001 | 162 | 2001 |
| A comparison between quantitative PCR and droplet digital PCR technologies for circulating microRNA quantification in human lung cancer P Campomenosi, E Gini, DM Noonan, A Poli, P D’Antona, N Rotolo, ... BMC biotechnology 16, 1-10, 2016 | 141 | 2016 |
| Characterization of RNASET2, the first human member of the Rh/T2/S family of glycoproteins P Campomenosi, S Salis, C Lindqvist, D Mariani, T Nordström, F Acquati, ... Archives of biochemistry and biophysics 449 (1-2), 17-26, 2006 | 84 | 2006 |
| Tumor and metastasis suppression by the human RNASET2 gene F Acquati, L Possati, L Ferrante, P Campomenosi, S Talevi, S Bardelli, ... International journal of oncology 26 (5), 1159-1168, 2005 | 82 | 2005 |
| Tumour p53 mutations exhibit promoter selective dominance over wild type p53 P Monti, P Campomenosi, Y Ciribilli, R Iannone, A Inga, A Abbondandolo, ... Oncogene 21 (11), 1641-1648, 2002 | 80 | 2002 |
| Microenvironmental control of malignancy exerted by RNASET2, a widely conserved extracellular RNase F Acquati, S Bertilaccio, A Grimaldi, L Monti, R Cinquetti, P Bonetti, ... Proceedings of the National Academy of Sciences 108 (3), 1104-1109, 2011 | 75 | 2011 |
| Amifostine (WR2721) restores transcriptional activity of specific p53 mutant proteins in a yeast functional assay D Maurici, P Monti, P Campomenosi, S North, T Frebourg, G Fronza, ... Oncogene 20 (27), 3533-3540, 2001 | 63 | 2001 |
| Systematic review and critique of circulating miRNAs as biomarkers of stage I-II non-small cell lung cancer F Moretti, P D’Antona, E Finardi, M Barbetta, L Dominioni, A Poli, E Gini, ... Oncotarget 8 (55), 94980, 2017 | 57 | 2017 |
| Characterization of the p53 mutants ability to inhibit p73β transactivation using a yeast-based functional assay P Monti, P Campomenosi, Y Ciribilli, R Iannone, A Aprile, A Inga, M Tada, ... Oncogene 22 (34), 5252-5260, 2003 | 56 | 2003 |
| p53 is frequently mutated in Barrett's metaplasia of the intestinal type. P Campomenosi, M Conio, M Bogliolo, S Urbini, P Assereto, A Aprile, ... Cancer epidemiology, biomarkers & prevention: a publication of the American …, 1996 | 56 | 1996 |
| The 4-nitroquinoline 1-oxide mutational spectrum in single stranded DNA is characterized by guanine to pyrimidine transversions G Fronza, P Campomenosi, R lannone, A Abbondandolo Nucleic acids research 20 (6), 1283-1287, 1992 | 56 | 1992 |
| Measurements methods for the development of MicroRNA-based tests for cancer diagnosis F Precazzini, S Detassis, AS Imperatori, MA Denti, P Campomenosi International journal of molecular sciences 22 (3), 1176, 2021 | 55 | 2021 |
| Signals of pseudo-starvation unveil the amino acid transporter SLC7A11 as key determinant in the control of Treg cell proliferative potential C Procaccini, S Garavelli, F Carbone, D Di Silvestre, C La Rocca, D Greco, ... Immunity 54 (7), 1543-1560. e6, 2021 | 53 | 2021 |
| The yeast p53 functional assay: a new tool for molecular epidemiology. Hopes and facts G Fronza, A Inga, P Monti, G Scott, P Campomenosi, P Menichini, ... Mutation Research/Reviews in Mutation Research 462 (2-3), 293-301, 2000 | 40 | 2000 |
| Proline oxidase controls proline, glutamate, and glutamine cellular concentrations in a U87 glioblastoma cell line P Cappelletti, E Tallarita, V Rabattoni, P Campomenosi, S Sacchi, ... PLoS One 13 (4), e0196283, 2018 | 34 | 2018 |
| P53 family members modulate the expression of PRODH, but not PRODH2, via intronic p53 response elements I Raimondi, Y Ciribilli, P Monti, A Bisio, L Pollegioni, G Fronza, A Inga, ... PLoS One 8 (7), e69152, 2013 | 34 | 2013 |
| TAS2R38 taste receptor gene and chronic rhinosinusitis: new data from an Italian population S Gallo, S Grossi, G Montrasio, G Binelli, R Cinquetti, D Simmen, ... BMC medical genetics 17, 1-7, 2016 | 33 | 2016 |
| Cancer biomarkers in human atherosclerotic lesions: no evidence of p53 involvement. F D'Agostini, G Fronza, P Campomenosi, A Izzotti, GL Petrilli, ... Cancer epidemiology, biomarkers & prevention: a publication of the American …, 1995 | 31 | 1995 |
| Study on aneuploidy and p53 mutations in astrocytonias P Campomenosi, L Ottaggio, F Moro, S Urbini, M Bogliolo, A Zunino, ... Cancer genetics and cytogenetics 88 (2), 95-102, 1996 | 30 | 1996 |
| The degradation (by distinct pathways) of human d‐amino acid oxidase and its interacting partner pLG72 – two key proteins in d‐serine catabolism in the brain P Cappelletti, P Campomenosi, L Pollegioni, S Sacchi The FEBS Journal 281 (3), 708-723, 2014 | 29 | 2014 |
